NIPH Clinical Trials Search

Prognostic Prediction of Patients with Steatotic Liver Disease Using 2D-SWE and UGAP

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	SLD
Date of first enrollment	26/12/2024
Target sample size	650
Countries of recruitment
Study type	Interventional
Intervention(s)	Using the image processing program installed in the ultrasound diagnostic equipment

Outcome(s)

Primary Outcome	The mortality rate
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	1. Patients with a confirmed diagnosis of NAFLD (non-alcoholic fatty liver disease), non-alcoholic steatohepatitis, or cirrhosis, including a history of NASH-related liver cancer based on histology or imaging. 2. Patients who can undergo regular blood and imaging tests once during the follow-up period (including three times if the follow-up period is three years, and five times if it is five years). 3. Patients aged 18 years or older at the time of consent. 4. Patients who have provided written consent fortrial participation.
Exclude criteria	1. Patients who are suffering from liver diseases other than NAFLD (non-alcoholic fatty liver disease), such as viral hepatitis or drug-induced fatty liver, and untreated hypothyroidism. 2. Male patients with an average daily alcohol consumption of 60 grams or more, or female patients with an average daily alcohol consumption of 50 g rams or more in the past 12 months. 3. Patients whom the principal investigator or co-investigator has deemed unsuitable for participation in this study